News for DiaMedica Therapeutics Inc. (DMAC)

Maine-based Synergy CHC Corp. (SNYR) is up over 139 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Shares of Telefonaktiebolaget LM Ericsson ERIC rose sharply in today's pre-market trading following first-quarter results. Ericsson reported that its first-qua...

Cash and Investments: $44.1 million as of December 31, 2024.Current Liabilities: $5.4 million as of December 31, 2024.Working Capital: $39.2 million as of Dece

Mar 18, 2025 / 12:00PM GMTRick Pauls - DiaMedica Therapeutics Inc - President, Chief Executive Officer, Director Thank you, operator. Hello everyone and welcome

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2024 Earnings Conference Call March 18, 2025 8:00 AM ETCompany ParticipantsRick Pauls - President and...

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and pre

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, ann

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and preeclampsia, today announced the e

DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsRick Pauls - President, Chief...

DiaMedica Therapeutics announced Q3 financial results, with total cash of $50.2 million and working capital of $46.5 million.

DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024

Aug 08, 2024 / 12:00PM GMTOperator Good morning ladies and gentlemen and welcome to the DiaMedica Therapeutics second quarter 2024 conference Call. An audio rec

DiaMedica Therapeutics Inc. (NASDAQ:NASDAQ:DMAC) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ETCompany ParticipantsRick Pauls - President, Chief...

Here is how DiaMedica Therapeutics, Inc. (DMAC) and Elutia Inc. (ELUT) have performed compared to their sector so far this year.

The surge in demand for intracranial stents is predominantly driven by the growing occurrence of neurological conditions like intracranial stenosis and...

An interim futility analysis by DSMB of DM199 for patients with AIS in the phase 2/3 ReMEDy2 trial is expected by Q1’25. Read more on DMAC stock here.

DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia

Earnings call: DiaMedica reports on ReMEDy2 trial progress and finances